Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 136 of 5804
-
Viruses vs. infections: new hope for implant troubles?
Disease control Not yet recruitingA Prospective, Single-Center, Single-Arm Clinical Study with a Pre-Post Self-Controlled Design Evaluating the Efficacy and Safety of Bacteriophage Therapy for Refractory Orthopedic Implant-Associated Infections
Phase: PHASE3 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
One shot to prevent cancer: new HPV vaccine tested in zambia
Prevention Not yet recruitingThe goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly…
Phase: PHASE4 • Sponsor: International Agency for Research on Cancer • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
New hope for young leukemia patients: targeted chemo combo aims to boost treatment success
Disease control Not yet recruitingThe goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * bli…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New vaccine aims to reverse HPV-Linked cervical changes without surgery
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System) in patients with biopsy-confirmed, human papilloma v…
Phase: PHASE2 • Sponsor: PapiVax Biotech, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New hope for elderly blood cancer patients: experimental transplant prep shows promise
Disease control Recruiting nowAcute myeloid leukemia (AML) is one of the most common hematologic malignancies. With increasing life expectancy and the aging of society, the incidence of AML in the elderly population is rising. The prognosis of elderly AML patients is significantly worse than that of younger p…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail aims to beat back aggressive throat cancer
Disease control Not yet recruitingThis randomized controlled trial aims to evaluate the efficacy and safety of Becotatug Vedotin (MRG003), an antibody-drug conjugate (ADC), combined with the PD-1 inhibitor Pucotenlimab as induction therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (NPC), comp…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo aims to keep leukemia away after remission
Disease control ENROLLING_BY_INVITATIONThis study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment of patients with AML after remission, providing hig…
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cocktail of drugs shows promise for deadly brain cancer
Disease control Recruiting nowPrimary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a rising trend in immunocompetent patients. First-lin…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare, aggressive stomach cancer: drug combo aims to make tumors operable
Disease control Not yet recruitingAlpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases. Its clinical features are significantly different from those of common gastric cancer. N…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to shrink tough breast cancer tumors
Disease control Not yet recruitingTitle: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or met…
Phase: PHASE2, PHASE3 • Sponsor: BeBetter Med Inc • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for lung cancer patients: combo therapy enters phase 3 trial
Disease control Not yet recruitingThis is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung canc…
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo treatment aims to reduce disability after brain hemorrhage
Disease control Not yet recruitingIntroduction: Minimally invasive puncture surgery with thrombolysis is effective for hypertensive intracerebral hemorrhage, but its effect on neurological recovery remains uncertain. The use of neuronavigation-assisted stereotactic technology can significantly improve the precisi…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to shrink liver tumors enough for surgery
Disease control Recruiting nowConversion therapy for unresectable intermediate-advanced hepatocellular carcinoma (uHCC) has evolved from systemic therapy to combined local-systemic approaches, but current regimens still have limited surgical conversion rates. This prospective, single-arm phase II study evalu…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New antibiotic cocktail takes on superbug pneumonia in hospitals
Disease control Recruiting nowThis is a two-part study, with Part A being the randomized, controlled portion of the study in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem-resistant Acinetobacter bau…
Phase: PHASE3 • Sponsor: BioVersys SAS • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy offers hope for untreatable liver cancer
Disease control Recruiting nowThis study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are…
Phase: PHASE2, PHASE3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug YL201 takes on tough esophageal cancer
Disease control Recruiting nowThis is a large clinical study carried out at multiple hospitals. Participants will be randomly assigned to one of two groups: one group will receive a new medicine called YL201, and the other group will receive standard chemotherapy chosen by the doctor. The purpose of the stud…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowResearchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and t…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New oral pill aims to clear psoriasis in major trial
Disease control Recruiting nowThe purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
Phase: PHASE3 • Sponsor: Zhejiang Wenda Pharma Technology LTD. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for advanced breast cancer: YL202 takes on standard treatments in major trial
Disease control Recruiting nowThe study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-po…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control Recruiting nowThe primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC